Related Experiment Video
Updated: Jun 14, 2026

An Ex vivo Assay to Study Candida albicans Hyphal Morphogenesis in the Gastrointestinal Tract
Published on: July 1, 2020
Prevalence and management of non-albicans vaginal candidiasis
Nalin Hettiarachchi1, Nalin Hetticarachchi, H Ruth Ashbee
1Department of Genitourinary Medicine, Leeds General Infirmary, Great George Street, Leeds LS1 3EX, UK.
Objectives:
It is thought that widespread use of 'over-the-counter' azoles may increase the incidence of resistant Candida species such as Candida glabrata. Infections with species other than Candida albicans frequently do not respond to standard azole treatments. Intravaginal nystatin is an option but is no longer available in the UK. In this paper, the authors review the prevalence of non-albicans candida over the past 5 years, and assess the efficacy of amphotericin and flucytosine vaginal cream in the treatment of non-albicans VVC.
Methods:
Retrospective review of all vaginal yeast isolates collected from women attending a city centre sexual-health clinic between 2004 and 2008. The women prescribed amphotericin and flucytosine vaginal cream were identified through pharmacy records, and their clinical notes reviewed for treatment outcome.
Results:
Between 2004 and 2008, the number of isolates of all Candida species increased with increasing clinic workload, but the prevalence of non-albicans yeasts remained stable at between 0.87 and 1.06%. Eighteen patients were prescribed amphotericin and flucytosine vaginal cream. At follow-up, all 18 were clear of their initial yeast isolate on culture, but two had persistent symptoms and had positive cultures for C albicans.
Conclusions:
There is no evidence of any increase in prevalence of non-albicans Candida species such as C glabrata. The authors have treated 18 women who had non-albicans VVC with amphotericin and flucytosine vaginal cream and achieved clearance of the non-albicans species in all of them.
Insights
Non-albicans Candida species, like Candida glabrata, remain stable in prevalence. Amphotericin and flucytosine vaginal cream effectively treated non-albicans vulvovaginal candidiasis (VVC) in 18 women.
Area of Science:
- Medical Mycology
- Infectious Diseases
- Pharmacology
Background:
- Widespread azole use may increase resistant Candida species, including Candida glabrata.
- Infections with non-albicans Candida species often resist standard azole treatments.
- Intravaginal nystatin is no longer available in the UK.
Purpose of the Study:
- To review the prevalence of non-albicans Candida over five years.
- To assess the efficacy of amphotericin and flucytosine vaginal cream for non-albicans VVC.
Main Methods:
- Retrospective review of vaginal yeast isolates from 2004-2008.
- Identification of patients prescribed amphotericin and flucytosine vaginal cream.
- Review of clinical notes for treatment outcomes.
Main Results:
- Non-albicans yeast prevalence remained stable (0.87-1.06%) between 2004-2008.
- All 18 patients treated with amphotericin and flucytosine cream cleared their initial yeast isolate.
- Two patients experienced persistent symptoms and positive Candida albicans cultures.
Conclusions:
- No evidence of increased prevalence for non-albicans Candida species like C. glabrata.
- Amphotericin and flucytosine vaginal cream achieved clearance of non-albicans species in all treated patients.
Related Concept Videos
Candidiasis
Cryptococcal Meningitis
Trichomoniasis
Genital Herpes
Fungal Phylum Microsporidia
Cytomegalovirus Disease
